Please select the option that best describes you:
What factors do you use to decide between trastuzumab-deruxtecan and sacituzumab govitecan in HER2-low metastatic breast cancer?
Is there any data on the efficacy of T-Dxd after progression on sacituzumab govitecan?
Does your approach differ by hormone receptor status now that both agents have shown efficacy HR+ and HR- disease?
Answer from: Medical Oncologist at Community Practice
Updated answer - 12/04/2024
Key factors include:
HER2 expression: T-DXd is preferred for HER2-low patients, as sacituzumab govitecan is not specifically studied in this subgroup.
Line of therapy: Sacituzumab govitecan is often used after multiple chemotherapy lines, while T-DXd may be utilized ...
Comments
Medical Oncologist at MedStar Washington Hospital Center, MedStar Georgetown University Hospital
Dr. @Ueno, Would incidental findings of traction ...
Dr. @Ueno, Would incidental findings of traction ...
Answer from: Medical Oncologist at Community Practice
Fam-trastuzumab deruxtecan (TDxd) and sacituzumab govitecan (SG) were and are being developed separately; in the course of their development, their paths collided leading to the key questions articulated above. There is no direct comparison between the 2 ADCs. The overarching hypotheses that led to ...
Answer from: Medical Oncologist at Community Practice
Tend to use T-Dxd in HER+ patients and sacituzumab in HER2 neg patients first.
Decreased efficacy of the second ADC (TDxd and sac...
Dato-Dxd approval will make choices even more comp...